Mednet Logo
SpecialtiesEndocrinology
Endocrinology

Endocrinology

Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.

Recent Discussions

Do you typically start PTH analogue therapy for osteoporosis at lower doses and gradually titrate up to improve tolerance and longer term use?

1 Answers

Mednet Member
Mednet Member
Endocrinology · Kaiser Permanente Oakland Medical Center Endocrinology

I usually start teriparatide 20 mcg daily. It is a prefilled pen so lower dose would be hard to do but for patients who have side effects, I give 20 mcg every other day for a few weeks and then increase it to 20 mcg daily.

For patients <65 with significant intermittent steroid exposure who otherwise do not have risk factors for osteoporosis, when, if ever, do you recommend considering DEXA screening?

2
2 Answers

Mednet Member
Mednet Member
Rheumatology · Sunshine Rheumatology & Arthritis Center

The FRAX guidelines recommend answering "Yes" for glucocorticoid use when a patient has received the equivalent of prednisone ≥5 mg daily for more than 3 months. However, many patients with rheumatoid arthritis have been treated with intermittent courses of corticosteroids over several years, which ...

How frequently would you check thyroid function in a patient who has been on amiodarone for more than one year with no prior thyroid disease and consistently normal thyroid function tests?

1 Answers

Mednet Member
Mednet Member
Endocrinology · Michigan State University College of Human Medicine

Amiodarone-induced thyroid dysfunction occurs in approximately 2–24% of cases. Hypothyroidism is more common than hyperthyroidism. Hypothyroidism can occur within 3 months of the beginning of Amiodarone in 10–20% of cases or may develop up to 1 year in 5–10% of cases. In some studies, the median tim...

What is your approach to treating concomitant hypernatremia and hyperglycemia in patients with encephalopathy?

1
1 Answers

Mednet Member
Mednet Member
Hospital Medicine · Yale School of Medicine/Yale-New Haven Hospital

The risk-benefit assessment begins by identifying the primary physiologic problem. In patients with concomitant hypernatremia and hyperglycemia, the dominant abnormality is usually a profound free water deficit from osmotic diuresis. My goal is to restore normal physiology by replacing that free wat...

How do you adjust your management strategy to address the unique needs of anuric end-stage kidney disease patients when treating diabetic ketoacidosis?

3
1 Answers

Mednet Member
Mednet Member
Nephrology · Rush Medical College

There is no osmotic diuresis, and they do not need IVFluid, the opposite is true they may appear intravascularly overloaded, and will respond to insulin alone, they do not need HD for this. They will not be K deficient, do not give K. Their potassium will likely respond to insulin alone, and should...

Do you recommend the use of CGM for monitoring of postbariatric hypoglycemia given recent evidence of reduced accuracy in dynamic postprandial conditions?

2 Answers

Mednet Member
Mednet Member
Endocrinology · Brigham And Womens Hospital Endocrinology

I have always been concerned about accurately detecting hypoglycemia in patients because of the higher MARD in the hypoglycemic range with most CGM sensors. A recent review found the MARD in hospitalized patients to be 15% in the hypoglycemic range, which is much higher than in the euglycemic or hyp...

When can we consider deferring an insulin drip in patients with hypertriglyceridemia-induced pancreatitis?

5
2 Answers

Mednet Member
Mednet Member
Hospital Medicine · Dartmouth-Hitchcock Medical Center

Serum triglyceride levels &gt;500 mg/dL (5.6 mmol/L) are required for hypertriglyceridemia to be considered the underlying etiology of acute pancreatitis (UpToDate).For patients with severe hypertriglyceridemic pancreatitis, such as those serum triglyceride levels &gt;1000 mg/dL plus lipase &gt;3 times the u...

Is there any role for bisphosphonate or alternative bone-modifying agents use in SMM in the absence of other indications for its use?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Harvard Medical School

The short answer is no, unless the patient has an indication like osteoporosis. Bisphosphonates have been evaluated in smoldering multiple myeloma in studies performed over 10 years ago. Treatment with pamidronate (D’Arena et al., 2011) or zoledronic acid (Musto et al., 2008) did not affect the time...

Do you add an SGLT2 inhibitor to mineralocorticoid receptor antagonist therapy in a patient with primary aldosteronism who is not a surgical candidate, given retrospective data showing significantly lower mortality and cardiorenal events with the combination?

1
1 Answers

Mednet Member
Mednet Member
Nephrology · UAB Medicine

I have expanded the use of SGLT2-INHs beyond the core indications of HFrEF, DM2, and proteinuric CKD to include CV risk reduction for those at higher risk. Patients with primary aldosteronism often have a high ASCVD risk by PREVENT risk calculator, and would benefit from SGLT2-INH use.

When do you check vitamin D levels in patients with depressive symptoms?

7
7 Answers

Mednet Member
Mednet Member
Psychiatry · Christiana Psychiatric Services

I routinely check 25-OH D in all my patients. Given that half the population is deficient and that we now know the role of vitamin D not only for bones but in mood, cognition, and immunity. We need to be aware of deficiencies and replete if low. Moreover, ideal levels are 60-80, not just over 29 as ...